Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 108 | 2022 | 1051 | 16.260 |
Why?
|
Lung Neoplasms | 155 | 2023 | 2260 | 14.560 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 110 | 2023 | 1073 | 14.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 130 | 2023 | 2434 | 13.800 |
Why?
|
Carcinoma, Squamous Cell | 77 | 2022 | 1075 | 9.120 |
Why?
|
Antineoplastic Agents | 75 | 2022 | 2351 | 5.190 |
Why?
|
Chemoradiotherapy | 33 | 2023 | 301 | 5.060 |
Why?
|
Neoplasm Recurrence, Local | 53 | 2023 | 1305 | 4.850 |
Why?
|
Small Cell Lung Carcinoma | 22 | 2023 | 98 | 4.550 |
Why?
|
Papillomavirus Infections | 12 | 2022 | 239 | 3.790 |
Why?
|
Carboplatin | 41 | 2022 | 286 | 3.500 |
Why?
|
Combined Modality Therapy | 63 | 2021 | 1680 | 3.200 |
Why?
|
Oropharyngeal Neoplasms | 8 | 2022 | 118 | 3.100 |
Why?
|
Paclitaxel | 41 | 2022 | 460 | 3.020 |
Why?
|
Quinazolines | 22 | 2015 | 220 | 2.990 |
Why?
|
ErbB Receptors | 33 | 2022 | 485 | 2.970 |
Why?
|
Protein Kinase Inhibitors | 22 | 2022 | 589 | 2.860 |
Why?
|
Aged | 187 | 2021 | 18353 | 2.810 |
Why?
|
Neoplasm Staging | 77 | 2023 | 1932 | 2.750 |
Why?
|
Disease-Free Survival | 58 | 2023 | 1203 | 2.690 |
Why?
|
Humans | 341 | 2023 | 86281 | 2.670 |
Why?
|
Adenocarcinoma | 26 | 2023 | 1160 | 2.560 |
Why?
|
Middle Aged | 190 | 2022 | 24957 | 2.510 |
Why?
|
Cetuximab | 15 | 2020 | 113 | 2.320 |
Why?
|
Aged, 80 and over | 100 | 2021 | 6481 | 2.230 |
Why?
|
Survival Rate | 54 | 2021 | 1856 | 2.210 |
Why?
|
Male | 207 | 2022 | 40860 | 2.210 |
Why?
|
Female | 209 | 2022 | 44405 | 2.090 |
Why?
|
Adult | 155 | 2023 | 25577 | 2.020 |
Why?
|
Antineoplastic Agents, Immunological | 8 | 2022 | 185 | 1.990 |
Why?
|
Papillomaviridae | 9 | 2022 | 153 | 1.980 |
Why?
|
Treatment Outcome | 88 | 2022 | 7949 | 1.940 |
Why?
|
Antibodies, Monoclonal | 21 | 2023 | 1376 | 1.790 |
Why?
|
Survival Analysis | 45 | 2020 | 1536 | 1.760 |
Why?
|
Clinical Trials as Topic | 24 | 2021 | 1168 | 1.760 |
Why?
|
Carcinoma, Small Cell | 11 | 2017 | 134 | 1.740 |
Why?
|
Induction Chemotherapy | 12 | 2022 | 147 | 1.730 |
Why?
|
Cisplatin | 31 | 2022 | 612 | 1.730 |
Why?
|
Taxoids | 17 | 2017 | 129 | 1.720 |
Why?
|
Indoles | 15 | 2017 | 318 | 1.710 |
Why?
|
Radiotherapy Dosage | 31 | 2023 | 468 | 1.670 |
Why?
|
Fluorouracil | 26 | 2022 | 556 | 1.660 |
Why?
|
Camptothecin | 14 | 2013 | 189 | 1.660 |
Why?
|
Hydroxyurea | 21 | 2022 | 239 | 1.500 |
Why?
|
Radiotherapy | 15 | 2011 | 326 | 1.500 |
Why?
|
Pyrroles | 7 | 2017 | 184 | 1.490 |
Why?
|
Carcinoma | 9 | 2022 | 434 | 1.430 |
Why?
|
Radiation-Sensitizing Agents | 6 | 2013 | 94 | 1.420 |
Why?
|
Biomarkers, Tumor | 21 | 2023 | 1461 | 1.410 |
Why?
|
Precision Medicine | 7 | 2021 | 394 | 1.320 |
Why?
|
Nasopharyngeal Neoplasms | 4 | 2023 | 47 | 1.280 |
Why?
|
Laryngeal Neoplasms | 5 | 2013 | 89 | 1.270 |
Why?
|
Medical Oncology | 8 | 2023 | 357 | 1.250 |
Why?
|
Prognosis | 47 | 2022 | 3669 | 1.220 |
Why?
|
Mouth Neoplasms | 9 | 2018 | 194 | 1.210 |
Why?
|
Deoxycytidine | 14 | 2012 | 237 | 1.190 |
Why?
|
Proto-Oncogene Proteins c-met | 16 | 2021 | 199 | 1.190 |
Why?
|
Drug Resistance, Neoplasm | 13 | 2021 | 589 | 1.180 |
Why?
|
Benzimidazoles | 4 | 2021 | 140 | 1.180 |
Why?
|
Chemotherapy, Adjuvant | 20 | 2015 | 468 | 1.170 |
Why?
|
Sirolimus | 3 | 2020 | 169 | 1.150 |
Why?
|
Maximum Tolerated Dose | 14 | 2022 | 270 | 1.110 |
Why?
|
Mesothelioma | 13 | 2017 | 309 | 1.090 |
Why?
|
Etoposide | 15 | 2021 | 196 | 1.080 |
Why?
|
Vascular Endothelial Growth Factor A | 11 | 2023 | 407 | 1.050 |
Why?
|
Pneumonectomy | 4 | 2023 | 195 | 1.010 |
Why?
|
DNA, Viral | 2 | 2023 | 265 | 1.000 |
Why?
|
Salvage Therapy | 9 | 2014 | 232 | 0.980 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2021 | 72 | 0.980 |
Why?
|
Neoplasms | 17 | 2022 | 2889 | 0.940 |
Why?
|
Esophageal Neoplasms | 5 | 2012 | 320 | 0.940 |
Why?
|
Guanine | 8 | 2014 | 208 | 0.930 |
Why?
|
Randomized Controlled Trials as Topic | 13 | 2023 | 850 | 0.900 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 50 | 0.900 |
Why?
|
Circulating Tumor DNA | 1 | 2023 | 37 | 0.890 |
Why?
|
Re-Irradiation | 1 | 2022 | 15 | 0.870 |
Why?
|
Clinical Trials, Phase II as Topic | 8 | 2017 | 173 | 0.870 |
Why?
|
Clinical Trials, Phase III as Topic | 10 | 2021 | 169 | 0.860 |
Why?
|
Quality of Life | 16 | 2017 | 1575 | 0.860 |
Why?
|
Antibodies, Monoclonal, Humanized | 18 | 2018 | 929 | 0.860 |
Why?
|
Deglutition | 9 | 2020 | 73 | 0.860 |
Why?
|
Neoplasms, Second Primary | 8 | 2011 | 252 | 0.850 |
Why?
|
Pancreatic Neoplasms | 4 | 2010 | 645 | 0.840 |
Why?
|
Angiogenesis Inhibitors | 9 | 2016 | 309 | 0.840 |
Why?
|
Disease Progression | 23 | 2023 | 1531 | 0.830 |
Why?
|
Radiotherapy, Conformal | 5 | 2011 | 83 | 0.830 |
Why?
|
Kaplan-Meier Estimate | 17 | 2017 | 859 | 0.820 |
Why?
|
Liver Neoplasms | 8 | 2018 | 731 | 0.800 |
Why?
|
Drug Monitoring | 2 | 2022 | 118 | 0.800 |
Why?
|
Neoplasm Metastasis | 19 | 2020 | 1056 | 0.790 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2022 | 69 | 0.770 |
Why?
|
Bevacizumab | 11 | 2017 | 281 | 0.760 |
Why?
|
Cyclooxygenase 2 | 4 | 2017 | 99 | 0.750 |
Why?
|
Carcinoma, Large Cell | 7 | 2014 | 39 | 0.740 |
Why?
|
Enzyme Inhibitors | 7 | 2014 | 632 | 0.720 |
Why?
|
Thyroid Neoplasms | 2 | 2023 | 406 | 0.720 |
Why?
|
Pemetrexed | 10 | 2020 | 76 | 0.720 |
Why?
|
Thoracic Neoplasms | 4 | 2018 | 64 | 0.690 |
Why?
|
Glutamates | 6 | 2014 | 89 | 0.650 |
Why?
|
Terminal Care | 1 | 2019 | 130 | 0.640 |
Why?
|
Drug Administration Schedule | 17 | 2020 | 916 | 0.630 |
Why?
|
Vinblastine | 3 | 2002 | 108 | 0.630 |
Why?
|
Organoplatinum Compounds | 4 | 2006 | 94 | 0.620 |
Why?
|
Follow-Up Studies | 24 | 2021 | 3616 | 0.620 |
Why?
|
Time Factors | 21 | 2021 | 5198 | 0.620 |
Why?
|
Erlotinib Hydrochloride | 11 | 2022 | 90 | 0.600 |
Why?
|
Stomach Neoplasms | 3 | 2011 | 266 | 0.590 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2014 | 378 | 0.580 |
Why?
|
Quality of Health Care | 2 | 2019 | 380 | 0.580 |
Why?
|
Human papillomavirus 16 | 2 | 2015 | 38 | 0.580 |
Why?
|
Colorectal Neoplasms | 5 | 2011 | 924 | 0.570 |
Why?
|
Thionucleotides | 2 | 2008 | 56 | 0.560 |
Why?
|
Organ Sparing Treatments | 2 | 2013 | 36 | 0.550 |
Why?
|
Neoadjuvant Therapy | 7 | 2022 | 315 | 0.550 |
Why?
|
Immunotherapy | 6 | 2021 | 627 | 0.550 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2011 | 20 | 0.540 |
Why?
|
Neoplasms, Squamous Cell | 2 | 2015 | 19 | 0.540 |
Why?
|
Radiotherapy, Adjuvant | 12 | 2015 | 291 | 0.530 |
Why?
|
Speech | 2 | 2013 | 84 | 0.520 |
Why?
|
Patient Selection | 8 | 2021 | 685 | 0.520 |
Why?
|
Remission Induction | 10 | 2014 | 722 | 0.510 |
Why?
|
Exanthema | 3 | 2014 | 36 | 0.500 |
Why?
|
Pleural Neoplasms | 5 | 2020 | 188 | 0.500 |
Why?
|
B7-H1 Antigen | 6 | 2023 | 250 | 0.500 |
Why?
|
Retrospective Studies | 27 | 2023 | 8431 | 0.500 |
Why?
|
Platinum Compounds | 3 | 2022 | 30 | 0.490 |
Why?
|
Pyridines | 5 | 2019 | 309 | 0.480 |
Why?
|
Lymph Nodes | 6 | 2023 | 530 | 0.480 |
Why?
|
Neck Dissection | 6 | 2010 | 65 | 0.470 |
Why?
|
Blood Proteins | 1 | 2014 | 144 | 0.460 |
Why?
|
Receptor Protein-Tyrosine Kinases | 5 | 2015 | 153 | 0.450 |
Why?
|
Neutropenia | 6 | 2017 | 215 | 0.440 |
Why?
|
Mutation | 18 | 2023 | 3952 | 0.440 |
Why?
|
Neoplasm Invasiveness | 6 | 2016 | 551 | 0.440 |
Why?
|
DNA Repair | 2 | 2014 | 356 | 0.440 |
Why?
|
Cell Line, Tumor | 20 | 2021 | 2421 | 0.440 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2016 | 173 | 0.430 |
Why?
|
Molecular Targeted Therapy | 3 | 2020 | 266 | 0.430 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 4 | 2023 | 68 | 0.430 |
Why?
|
Platinum | 7 | 2022 | 63 | 0.430 |
Why?
|
Protein-Tyrosine Kinases | 6 | 2017 | 302 | 0.430 |
Why?
|
Proteomics | 1 | 2014 | 211 | 0.420 |
Why?
|
Antimetabolites, Antineoplastic | 4 | 2013 | 236 | 0.420 |
Why?
|
DNA-Binding Proteins | 3 | 2015 | 1208 | 0.420 |
Why?
|
Biomarkers | 4 | 2014 | 1709 | 0.420 |
Why?
|
Healthcare Disparities | 1 | 2016 | 369 | 0.420 |
Why?
|
Publishing | 1 | 2013 | 90 | 0.420 |
Why?
|
Sulfonamides | 9 | 2014 | 299 | 0.420 |
Why?
|
Radiosurgery | 3 | 2021 | 272 | 0.400 |
Why?
|
Proto-Oncogene Proteins c-cbl | 3 | 2017 | 36 | 0.400 |
Why?
|
Gene Expression Regulation, Neoplastic | 11 | 2017 | 1196 | 0.400 |
Why?
|
Signal Transduction | 11 | 2019 | 3233 | 0.390 |
Why?
|
Receptors, Growth Factor | 5 | 2011 | 52 | 0.390 |
Why?
|
Lung | 3 | 2013 | 1167 | 0.390 |
Why?
|
Proportional Hazards Models | 9 | 2019 | 857 | 0.390 |
Why?
|
Antineoplastic Agents, Phytogenic | 5 | 2012 | 276 | 0.380 |
Why?
|
Area Under Curve | 6 | 2018 | 334 | 0.380 |
Why?
|
Alphapapillomavirus | 2 | 2021 | 45 | 0.380 |
Why?
|
Methotrexate | 2 | 2017 | 249 | 0.360 |
Why?
|
Maintenance Chemotherapy | 3 | 2020 | 76 | 0.360 |
Why?
|
Receptor, EphB4 | 3 | 2015 | 24 | 0.360 |
Why?
|
Age Factors | 7 | 2018 | 1842 | 0.360 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2018 | 1958 | 0.350 |
Why?
|
Piperazines | 8 | 2019 | 272 | 0.340 |
Why?
|
Proto-Oncogene Proteins | 5 | 2017 | 645 | 0.340 |
Why?
|
Carmustine | 2 | 2006 | 70 | 0.340 |
Why?
|
Immunoconjugates | 2 | 2021 | 106 | 0.340 |
Why?
|
Administration, Oral | 9 | 2020 | 683 | 0.340 |
Why?
|
Cohort Studies | 10 | 2021 | 2759 | 0.340 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 2 | 2006 | 118 | 0.340 |
Why?
|
Immunologic Factors | 3 | 2023 | 170 | 0.340 |
Why?
|
Oxides | 1 | 2008 | 43 | 0.330 |
Why?
|
Arsenicals | 1 | 2008 | 48 | 0.330 |
Why?
|
Prospective Studies | 13 | 2022 | 4194 | 0.330 |
Why?
|
Immunohistochemistry | 10 | 2020 | 1752 | 0.330 |
Why?
|
Fatigue | 3 | 2018 | 174 | 0.320 |
Why?
|
Infusions, Intravenous | 8 | 2018 | 429 | 0.320 |
Why?
|
Salivary Gland Neoplasms | 4 | 2011 | 66 | 0.320 |
Why?
|
Smoking | 6 | 2014 | 605 | 0.320 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2023 | 455 | 0.320 |
Why?
|
Peritoneal Neoplasms | 4 | 2012 | 175 | 0.320 |
Why?
|
International Cooperation | 3 | 2018 | 126 | 0.310 |
Why?
|
Indazoles | 4 | 2013 | 68 | 0.310 |
Why?
|
Prostatic Neoplasms | 5 | 2011 | 1708 | 0.300 |
Why?
|
Suramin | 2 | 2004 | 27 | 0.300 |
Why?
|
Young Adult | 10 | 2022 | 5961 | 0.300 |
Why?
|
Alkyl and Aryl Transferases | 2 | 2003 | 15 | 0.300 |
Why?
|
Pyrimidines | 4 | 2012 | 370 | 0.300 |
Why?
|
DNA | 1 | 2012 | 1293 | 0.290 |
Why?
|
Phosphorylcholine | 1 | 2006 | 28 | 0.290 |
Why?
|
Niacinamide | 5 | 2013 | 116 | 0.280 |
Why?
|
Practice Guidelines as Topic | 3 | 2016 | 1030 | 0.280 |
Why?
|
Risk Factors | 12 | 2018 | 5397 | 0.280 |
Why?
|
Multivariate Analysis | 8 | 2019 | 997 | 0.280 |
Why?
|
Thiazoles | 3 | 2012 | 131 | 0.280 |
Why?
|
Deglutition Disorders | 4 | 2011 | 115 | 0.280 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 104 | 0.280 |
Why?
|
Benzenesulfonates | 3 | 2010 | 66 | 0.280 |
Why?
|
Anemia | 4 | 2017 | 128 | 0.280 |
Why?
|
Gallbladder Neoplasms | 1 | 2005 | 22 | 0.270 |
Why?
|
Tubulin Modulators | 2 | 2021 | 24 | 0.270 |
Why?
|
Mouth | 2 | 2018 | 48 | 0.270 |
Why?
|
Dacarbazine | 1 | 2006 | 102 | 0.270 |
Why?
|
Double-Blind Method | 5 | 2017 | 1822 | 0.270 |
Why?
|
Neovascularization, Pathologic | 2 | 2008 | 352 | 0.260 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2010 | 189 | 0.260 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 138 | 0.260 |
Why?
|
Confidence Intervals | 5 | 2018 | 228 | 0.250 |
Why?
|
Bile Duct Neoplasms | 1 | 2005 | 79 | 0.250 |
Why?
|
Oligopeptides | 1 | 2005 | 179 | 0.250 |
Why?
|
Imidazoles | 4 | 2013 | 163 | 0.250 |
Why?
|
Boronic Acids | 3 | 2011 | 54 | 0.250 |
Why?
|
Radiation Dosage | 3 | 2020 | 227 | 0.250 |
Why?
|
Herpesvirus 4, Human | 2 | 2023 | 114 | 0.250 |
Why?
|
Cyclosporine | 1 | 2005 | 234 | 0.250 |
Why?
|
Feasibility Studies | 4 | 2022 | 751 | 0.250 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2017 | 458 | 0.250 |
Why?
|
Pyrazines | 3 | 2011 | 84 | 0.240 |
Why?
|
Sarcoma | 1 | 2006 | 211 | 0.240 |
Why?
|
Radiography | 4 | 2014 | 812 | 0.240 |
Why?
|
Mouthwashes | 1 | 2003 | 5 | 0.240 |
Why?
|
United States | 12 | 2022 | 6637 | 0.240 |
Why?
|
Tretinoin | 2 | 2021 | 125 | 0.240 |
Why?
|
Positron-Emission Tomography | 2 | 2018 | 329 | 0.240 |
Why?
|
Viral Vaccines | 1 | 2003 | 43 | 0.230 |
Why?
|
Cancer Care Facilities | 1 | 2003 | 28 | 0.230 |
Why?
|
Immunoblotting | 5 | 2017 | 267 | 0.230 |
Why?
|
Travel | 1 | 2003 | 68 | 0.230 |
Why?
|
Gene Expression | 5 | 2017 | 1281 | 0.230 |
Why?
|
Tongue Neoplasms | 3 | 2018 | 50 | 0.220 |
Why?
|
Phosphorylation | 7 | 2017 | 1101 | 0.220 |
Why?
|
Quinolones | 1 | 2003 | 60 | 0.220 |
Why?
|
Iodine Radioisotopes | 1 | 2023 | 134 | 0.220 |
Why?
|
Brain Neoplasms | 3 | 2012 | 763 | 0.220 |
Why?
|
Attitude to Health | 1 | 2004 | 220 | 0.220 |
Why?
|
Chicago | 4 | 2014 | 1377 | 0.210 |
Why?
|
Drug Eruptions | 2 | 2017 | 35 | 0.210 |
Why?
|
Melanoma | 2 | 2005 | 454 | 0.210 |
Why?
|
Precancerous Conditions | 1 | 2003 | 196 | 0.210 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2020 | 182 | 0.210 |
Why?
|
Diffusion of Innovation | 1 | 2022 | 71 | 0.210 |
Why?
|
Cranial Irradiation | 3 | 2018 | 36 | 0.210 |
Why?
|
Albumins | 1 | 2022 | 133 | 0.210 |
Why?
|
Loss of Function Mutation | 1 | 2021 | 42 | 0.200 |
Why?
|
Network Meta-Analysis | 1 | 2021 | 7 | 0.200 |
Why?
|
Thrombocytopenia | 2 | 2017 | 183 | 0.200 |
Why?
|
Polymorphism, Genetic | 4 | 2011 | 819 | 0.200 |
Why?
|
Focal Adhesions | 2 | 2013 | 69 | 0.200 |
Why?
|
Erythroid Precursor Cells | 1 | 2021 | 32 | 0.200 |
Why?
|
Genomics | 3 | 2016 | 710 | 0.200 |
Why?
|
Adolescent | 7 | 2022 | 8968 | 0.200 |
Why?
|
Consolidation Chemotherapy | 2 | 2018 | 22 | 0.200 |
Why?
|
Research Report | 1 | 2021 | 44 | 0.190 |
Why?
|
RNA, Small Interfering | 8 | 2017 | 547 | 0.190 |
Why?
|
Sex Factors | 4 | 2019 | 1053 | 0.190 |
Why?
|
Paxillin | 2 | 2013 | 59 | 0.190 |
Why?
|
Endpoint Determination | 2 | 2023 | 60 | 0.190 |
Why?
|
Infant | 2 | 2023 | 3036 | 0.190 |
Why?
|
Pyrrolidinones | 1 | 2020 | 16 | 0.190 |
Why?
|
Placebos | 5 | 2015 | 218 | 0.190 |
Why?
|
Research Design | 4 | 2015 | 594 | 0.180 |
Why?
|
Recurrence | 1 | 2023 | 1137 | 0.180 |
Why?
|
Topoisomerase I Inhibitors | 5 | 2013 | 33 | 0.180 |
Why?
|
Immunosuppressive Agents | 1 | 2005 | 977 | 0.180 |
Why?
|
Gene Rearrangement | 2 | 2017 | 170 | 0.180 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 1671 | 0.180 |
Why?
|
Aminopyridines | 1 | 2019 | 32 | 0.180 |
Why?
|
Morpholines | 1 | 2019 | 65 | 0.180 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 387 | 0.170 |
Why?
|
Quinolines | 1 | 2020 | 95 | 0.170 |
Why?
|
Mucositis | 2 | 2017 | 17 | 0.170 |
Why?
|
Survival | 3 | 2003 | 21 | 0.170 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 153 | 0.170 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2011 | 165 | 0.170 |
Why?
|
Pharynx | 1 | 2018 | 45 | 0.170 |
Why?
|
Hepatocyte Growth Factor | 3 | 2014 | 84 | 0.170 |
Why?
|
Epothilones | 2 | 2009 | 13 | 0.170 |
Why?
|
Erythropoietin | 3 | 2013 | 91 | 0.170 |
Why?
|
Radiation Injuries | 2 | 2018 | 155 | 0.170 |
Why?
|
Phenylurea Compounds | 4 | 2013 | 113 | 0.170 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 3 | 2009 | 81 | 0.170 |
Why?
|
Gene Dosage | 7 | 2013 | 207 | 0.160 |
Why?
|
Depsipeptides | 2 | 2010 | 29 | 0.160 |
Why?
|
Dental Alloys | 1 | 2018 | 5 | 0.160 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 176 | 0.160 |
Why?
|
Orthodontic Appliances | 1 | 2018 | 7 | 0.160 |
Why?
|
Hemoptysis | 1 | 2018 | 24 | 0.160 |
Why?
|
Everolimus | 2 | 2022 | 40 | 0.160 |
Why?
|
Skin Neoplasms | 2 | 2005 | 541 | 0.160 |
Why?
|
Radiation Pneumonitis | 1 | 2018 | 21 | 0.160 |
Why?
|
DNA Topoisomerases, Type I | 3 | 2013 | 23 | 0.160 |
Why?
|
Ipilimumab | 3 | 2023 | 58 | 0.160 |
Why?
|
Macrophages | 1 | 2021 | 554 | 0.160 |
Why?
|
Mice | 11 | 2021 | 11313 | 0.160 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 1381 | 0.160 |
Why?
|
Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 25 | 0.160 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 415 | 0.160 |
Why?
|
Vision Disorders | 1 | 2018 | 75 | 0.160 |
Why?
|
Transforming Growth Factor alpha | 2 | 2009 | 50 | 0.150 |
Why?
|
Animals | 14 | 2021 | 26518 | 0.150 |
Why?
|
Retreatment | 3 | 2012 | 107 | 0.150 |
Why?
|
Odds Ratio | 4 | 2008 | 677 | 0.150 |
Why?
|
Mice, Nude | 4 | 2012 | 790 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 4 | 2013 | 2594 | 0.150 |
Why?
|
Pyrazoles | 3 | 2011 | 153 | 0.150 |
Why?
|
Carcinoma, Renal Cell | 3 | 2007 | 425 | 0.150 |
Why?
|
Geriatric Assessment | 1 | 2018 | 166 | 0.150 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 72 | 0.150 |
Why?
|
Life Style | 1 | 2018 | 188 | 0.150 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2012 | 348 | 0.150 |
Why?
|
Statistics, Nonparametric | 3 | 2009 | 307 | 0.140 |
Why?
|
Paired Box Transcription Factors | 2 | 2014 | 50 | 0.140 |
Why?
|
Celecoxib | 4 | 2017 | 31 | 0.140 |
Why?
|
Lymphatic Metastasis | 4 | 2014 | 480 | 0.140 |
Why?
|
Recombinant Proteins | 5 | 2010 | 1014 | 0.140 |
Why?
|
Carcinoma, Adenoid Cystic | 2 | 2007 | 28 | 0.140 |
Why?
|
Probability | 3 | 2008 | 355 | 0.140 |
Why?
|
SEER Program | 1 | 2016 | 181 | 0.140 |
Why?
|
Cell Movement | 6 | 2017 | 756 | 0.140 |
Why?
|
Kidney Neoplasms | 3 | 2007 | 620 | 0.140 |
Why?
|
Fractals | 1 | 2015 | 42 | 0.130 |
Why?
|
Cell Proliferation | 8 | 2015 | 1571 | 0.130 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 22 | 0.130 |
Why?
|
Health Status | 2 | 2009 | 360 | 0.130 |
Why?
|
Incidence | 5 | 2018 | 1568 | 0.130 |
Why?
|
Mass Screening | 2 | 2013 | 615 | 0.130 |
Why?
|
Platelet-Derived Growth Factor | 2 | 2011 | 67 | 0.130 |
Why?
|
Bryostatins | 2 | 2006 | 15 | 0.130 |
Why?
|
Bortezomib | 3 | 2011 | 75 | 0.130 |
Why?
|
Injections, Intravenous | 2 | 2006 | 243 | 0.130 |
Why?
|
Preoperative Care | 3 | 2009 | 390 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2017 | 371 | 0.130 |
Why?
|
Radiation, Ionizing | 2 | 2012 | 121 | 0.130 |
Why?
|
Treatment Failure | 5 | 2010 | 284 | 0.120 |
Why?
|
Isotretinoin | 2 | 2006 | 23 | 0.120 |
Why?
|
Gene Knockout Techniques | 1 | 2014 | 77 | 0.120 |
Why?
|
Cell Survival | 5 | 2017 | 966 | 0.120 |
Why?
|
Risk Assessment | 7 | 2016 | 2253 | 0.120 |
Why?
|
Tumor Virus Infections | 1 | 2014 | 81 | 0.120 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 567 | 0.120 |
Why?
|
Forecasting | 2 | 2021 | 303 | 0.120 |
Why?
|
Gene Amplification | 2 | 2018 | 131 | 0.120 |
Why?
|
Glucuronosyltransferase | 2 | 2006 | 184 | 0.120 |
Why?
|
Cyclooxygenase 2 Inhibitors | 2 | 2017 | 33 | 0.120 |
Why?
|
Population Groups | 1 | 2013 | 41 | 0.120 |
Why?
|
Farnesyltranstransferase | 2 | 2003 | 6 | 0.120 |
Why?
|
Alcohol Drinking | 3 | 2018 | 264 | 0.120 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2013 | 15 | 0.120 |
Why?
|
Leukocytes, Mononuclear | 2 | 2005 | 196 | 0.120 |
Why?
|
Interferon-alpha | 3 | 2010 | 233 | 0.120 |
Why?
|
Erythropoiesis | 1 | 2013 | 52 | 0.120 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 267 | 0.110 |
Why?
|
Gene Deletion | 1 | 2014 | 328 | 0.110 |
Why?
|
Clinical Protocols | 1 | 2013 | 155 | 0.110 |
Why?
|
Dehydration | 1 | 2013 | 18 | 0.110 |
Why?
|
HeLa Cells | 1 | 2014 | 498 | 0.110 |
Why?
|
Pharmacogenetics | 2 | 2008 | 434 | 0.110 |
Why?
|
Esophagitis | 1 | 2013 | 42 | 0.110 |
Why?
|
Proton Therapy | 1 | 2013 | 27 | 0.110 |
Why?
|
Mitochondrial Dynamics | 1 | 2013 | 53 | 0.110 |
Why?
|
Universities | 2 | 2010 | 135 | 0.110 |
Why?
|
Osteoradionecrosis | 2 | 2010 | 18 | 0.110 |
Why?
|
Keratin-19 | 1 | 2012 | 9 | 0.110 |
Why?
|
Ketones | 1 | 2012 | 13 | 0.110 |
Why?
|
Furans | 1 | 2012 | 16 | 0.110 |
Why?
|
Dexamethasone | 2 | 2004 | 326 | 0.110 |
Why?
|
Radiation Tolerance | 2 | 2021 | 168 | 0.110 |
Why?
|
DNA Mutational Analysis | 5 | 2017 | 526 | 0.110 |
Why?
|
Surveys and Questionnaires | 3 | 2018 | 2495 | 0.110 |
Why?
|
Multimodal Imaging | 1 | 2013 | 110 | 0.110 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 44 | 0.110 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2011 | 22 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2007 | 429 | 0.100 |
Why?
|
Genetic Testing | 1 | 2016 | 535 | 0.100 |
Why?
|
RNA, Viral | 1 | 2013 | 327 | 0.100 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2015 | 1200 | 0.100 |
Why?
|
Prostate-Specific Antigen | 2 | 2004 | 346 | 0.100 |
Why?
|
Phthalazines | 1 | 2011 | 39 | 0.100 |
Why?
|
Cancer Vaccines | 1 | 2013 | 156 | 0.100 |
Why?
|
Radiotherapy, Image-Guided | 1 | 2012 | 56 | 0.100 |
Why?
|
Ovarian Neoplasms | 2 | 2008 | 738 | 0.100 |
Why?
|
Organ Preservation | 1 | 2011 | 81 | 0.100 |
Why?
|
Genes, ras | 1 | 2011 | 96 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.100 |
Why?
|
Rad51 Recombinase | 2 | 2014 | 80 | 0.100 |
Why?
|
Analysis of Variance | 3 | 2011 | 912 | 0.100 |
Why?
|
Periodicals as Topic | 1 | 2013 | 167 | 0.100 |
Why?
|
Community Networks | 2 | 2018 | 29 | 0.090 |
Why?
|
Genetic Therapy | 1 | 2012 | 342 | 0.090 |
Why?
|
Receptor, EphA2 | 1 | 2010 | 6 | 0.090 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2011 | 128 | 0.090 |
Why?
|
Mucins | 1 | 2010 | 39 | 0.090 |
Why?
|
Developing Countries | 1 | 2010 | 69 | 0.090 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2010 | 111 | 0.090 |
Why?
|
Carcinosarcoma | 1 | 2010 | 20 | 0.090 |
Why?
|
Antigens, Neoplasm | 1 | 2012 | 324 | 0.090 |
Why?
|
Tissue Array Analysis | 3 | 2017 | 124 | 0.090 |
Why?
|
Disease Models, Animal | 4 | 2021 | 2227 | 0.090 |
Why?
|
Diarrhea | 3 | 2008 | 181 | 0.090 |
Why?
|
Postoperative Complications | 2 | 2018 | 2183 | 0.090 |
Why?
|
Postoperative Period | 1 | 2010 | 303 | 0.090 |
Why?
|
ras Proteins | 1 | 2010 | 128 | 0.090 |
Why?
|
Health Facilities | 1 | 2009 | 38 | 0.090 |
Why?
|
Biliary Tract Neoplasms | 1 | 2009 | 33 | 0.090 |
Why?
|
Hematopoietic Stem Cells | 1 | 2011 | 292 | 0.090 |
Why?
|
PAX5 Transcription Factor | 1 | 2009 | 32 | 0.090 |
Why?
|
Genotype | 5 | 2015 | 1850 | 0.090 |
Why?
|
Mesna | 1 | 2008 | 9 | 0.090 |
Why?
|
Gene Knockdown Techniques | 3 | 2017 | 234 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2010 | 321 | 0.080 |
Why?
|
Radiotherapy, High-Energy | 1 | 2008 | 49 | 0.080 |
Why?
|
Enteral Nutrition | 2 | 2020 | 102 | 0.080 |
Why?
|
Clinical Decision-Making | 2 | 2021 | 255 | 0.080 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2008 | 25 | 0.080 |
Why?
|
Macrolides | 2 | 2012 | 31 | 0.080 |
Why?
|
Receptor, ErbB-2 | 2 | 2011 | 223 | 0.080 |
Why?
|
Skin | 1 | 2012 | 554 | 0.080 |
Why?
|
Patient Care | 1 | 2009 | 100 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2010 | 276 | 0.080 |
Why?
|
Eicosanoids | 1 | 2008 | 16 | 0.080 |
Why?
|
Pain | 2 | 2017 | 389 | 0.080 |
Why?
|
Lipoxygenase Inhibitors | 1 | 2008 | 33 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2010 | 261 | 0.080 |
Why?
|
Hypertension | 1 | 2017 | 1139 | 0.080 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2008 | 35 | 0.080 |
Why?
|
Pneumonia, Aspiration | 1 | 2007 | 19 | 0.080 |
Why?
|
Models, Biological | 2 | 2015 | 1748 | 0.080 |
Why?
|
Technology, Radiologic | 1 | 2008 | 103 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2010 | 380 | 0.080 |
Why?
|
Protein Kinase C | 1 | 2008 | 270 | 0.080 |
Why?
|
Lung Diseases | 1 | 2009 | 263 | 0.080 |
Why?
|
Regression Analysis | 1 | 2009 | 595 | 0.080 |
Why?
|
Tumor Burden | 3 | 2013 | 288 | 0.080 |
Why?
|
Azacitidine | 1 | 2008 | 137 | 0.080 |
Why?
|
Epidermal Growth Factor | 1 | 2007 | 119 | 0.080 |
Why?
|
Tongue | 1 | 2007 | 57 | 0.080 |
Why?
|
Dasatinib | 3 | 2012 | 37 | 0.080 |
Why?
|
Oncogenes | 1 | 2007 | 88 | 0.070 |
Why?
|
Multienzyme Complexes | 2 | 2004 | 64 | 0.070 |
Why?
|
Biopsy | 3 | 2023 | 1160 | 0.070 |
Why?
|
Triazines | 1 | 2007 | 47 | 0.070 |
Why?
|
DNA Primers | 3 | 2014 | 542 | 0.070 |
Why?
|
Cysteine Endopeptidases | 2 | 2004 | 87 | 0.070 |
Why?
|
Base Sequence | 4 | 2014 | 2329 | 0.070 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2004 | 99 | 0.070 |
Why?
|
Matrix Metalloproteinase Inhibitors | 1 | 2006 | 14 | 0.070 |
Why?
|
Genes, Tumor Suppressor | 1 | 2007 | 157 | 0.070 |
Why?
|
Tachycardia, Supraventricular | 1 | 2006 | 16 | 0.070 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2006 | 23 | 0.070 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2006 | 40 | 0.070 |
Why?
|
Surgical Flaps | 1 | 2008 | 238 | 0.070 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2019 | 159 | 0.070 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 125 | 0.070 |
Why?
|
Uterine Neoplasms | 1 | 2010 | 225 | 0.070 |
Why?
|
Phospholipids | 1 | 2006 | 111 | 0.070 |
Why?
|
Illinois | 2 | 2007 | 461 | 0.070 |
Why?
|
Activin Receptors, Type I | 1 | 2005 | 12 | 0.070 |
Why?
|
Physician's Role | 1 | 2007 | 179 | 0.070 |
Why?
|
Observation | 2 | 2020 | 37 | 0.070 |
Why?
|
Leiomyosarcoma | 1 | 2006 | 40 | 0.070 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2005 | 40 | 0.070 |
Why?
|
Anticarcinogenic Agents | 1 | 2006 | 70 | 0.070 |
Why?
|
Societies, Medical | 2 | 2007 | 572 | 0.070 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2007 | 302 | 0.070 |
Why?
|
Algorithms | 3 | 2013 | 1828 | 0.070 |
Why?
|
Interleukin-2 | 1 | 2006 | 249 | 0.070 |
Why?
|
Carbon Monoxide | 1 | 2005 | 90 | 0.070 |
Why?
|
Cholangiocarcinoma | 1 | 2005 | 66 | 0.060 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2005 | 16 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2005 | 79 | 0.060 |
Why?
|
Drug Interactions | 1 | 2005 | 248 | 0.060 |
Why?
|
Hemorrhage | 1 | 2006 | 265 | 0.060 |
Why?
|
Radiometry | 1 | 2004 | 53 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2006 | 1801 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2018 | 188 | 0.060 |
Why?
|
Speech Intelligibility | 1 | 2004 | 10 | 0.060 |
Why?
|
Oligonucleotides, Antisense | 1 | 2004 | 69 | 0.060 |
Why?
|
Voice | 1 | 2004 | 20 | 0.060 |
Why?
|
Pyrrolidines | 1 | 2004 | 58 | 0.060 |
Why?
|
Amino Acid Sequence | 3 | 2015 | 2062 | 0.060 |
Why?
|
Leukemia | 1 | 2006 | 318 | 0.060 |
Why?
|
Taste | 1 | 2004 | 28 | 0.060 |
Why?
|
Loss of Heterozygosity | 2 | 2017 | 85 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2004 | 156 | 0.060 |
Why?
|
Logistic Models | 3 | 2018 | 1184 | 0.060 |
Why?
|
Nausea | 1 | 2005 | 175 | 0.060 |
Why?
|
Administration, Topical | 1 | 2003 | 94 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 2004 | 72 | 0.060 |
Why?
|
Fibroblast Growth Factors | 1 | 2004 | 80 | 0.060 |
Why?
|
Biopsy, Needle | 1 | 2004 | 234 | 0.060 |
Why?
|
Vomiting | 1 | 2005 | 193 | 0.060 |
Why?
|
Contrast Media | 2 | 2009 | 1076 | 0.060 |
Why?
|
DNA Methylation | 1 | 2008 | 622 | 0.060 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2005 | 164 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 68 | 0.060 |
Why?
|
Intubation, Gastrointestinal | 1 | 2003 | 31 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2006 | 322 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2010 | 689 | 0.060 |
Why?
|
Lactones | 1 | 2003 | 28 | 0.060 |
Why?
|
In Situ Hybridization | 1 | 2003 | 307 | 0.060 |
Why?
|
Mastication | 1 | 2004 | 76 | 0.060 |
Why?
|
Premedication | 1 | 2003 | 54 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2005 | 427 | 0.060 |
Why?
|
Mouth Mucosa | 1 | 2003 | 66 | 0.060 |
Why?
|
Hospitals, University | 1 | 2003 | 193 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2004 | 150 | 0.060 |
Why?
|
Bias | 1 | 2003 | 127 | 0.060 |
Why?
|
Cause of Death | 1 | 2004 | 277 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 893 | 0.050 |
Why?
|
STAT3 Transcription Factor | 2 | 2013 | 78 | 0.050 |
Why?
|
Adenoviridae | 1 | 2003 | 345 | 0.050 |
Why?
|
Uncertainty | 1 | 2022 | 71 | 0.050 |
Why?
|
Patient Care Team | 1 | 2005 | 280 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2003 | 222 | 0.050 |
Why?
|
RNA Interference | 2 | 2017 | 368 | 0.050 |
Why?
|
Registries | 1 | 2006 | 702 | 0.050 |
Why?
|
Education, Medical, Continuing | 1 | 2003 | 107 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2003 | 255 | 0.050 |
Why?
|
Pilot Projects | 2 | 2019 | 837 | 0.050 |
Why?
|
Adaptation, Psychological | 1 | 2002 | 157 | 0.050 |
Why?
|
Receptors, CCR2 | 1 | 2021 | 35 | 0.050 |
Why?
|
Smokers | 1 | 2021 | 41 | 0.050 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2005 | 380 | 0.050 |
Why?
|
Apoptosis | 3 | 2014 | 1678 | 0.050 |
Why?
|
DNA Damage | 2 | 2014 | 362 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2003 | 326 | 0.050 |
Why?
|
Protein Structure, Tertiary | 2 | 2015 | 736 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2003 | 347 | 0.050 |
Why?
|
T-Lymphocytes | 2 | 2006 | 1195 | 0.050 |
Why?
|
Comorbidity | 1 | 2004 | 943 | 0.050 |
Why?
|
Administration, Intravenous | 1 | 2020 | 50 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2011 | 155 | 0.050 |
Why?
|
Adaptive Immunity | 1 | 2021 | 164 | 0.040 |
Why?
|
Interferon-gamma | 1 | 2021 | 444 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2003 | 683 | 0.040 |
Why?
|
Health Resources | 1 | 2019 | 76 | 0.040 |
Why?
|
Sulindac | 2 | 2009 | 10 | 0.040 |
Why?
|
Epithelial Cells | 1 | 2022 | 662 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 425 | 0.040 |
Why?
|
Oral Health | 1 | 2018 | 10 | 0.040 |
Why?
|
Models, Molecular | 2 | 2015 | 1284 | 0.040 |
Why?
|
Age of Onset | 1 | 2018 | 306 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2021 | 503 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2019 | 202 | 0.040 |
Why?
|
Transfection | 2 | 2010 | 895 | 0.040 |
Why?
|
Anorexia | 1 | 2017 | 30 | 0.040 |
Why?
|
Social Participation | 1 | 2017 | 14 | 0.040 |
Why?
|
Cooperative Behavior | 2 | 2009 | 174 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 556 | 0.040 |
Why?
|
Metals | 1 | 2018 | 90 | 0.040 |
Why?
|
Sensation Disorders | 1 | 2017 | 23 | 0.040 |
Why?
|
Dinoprostone | 1 | 2017 | 69 | 0.040 |
Why?
|
Weight Loss | 1 | 2019 | 229 | 0.040 |
Why?
|
Proteolysis | 1 | 2017 | 100 | 0.040 |
Why?
|
Transcriptome | 1 | 2021 | 574 | 0.040 |
Why?
|
Dyspnea | 1 | 2017 | 72 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 237 | 0.040 |
Why?
|
ROC Curve | 1 | 2019 | 752 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2009 | 927 | 0.040 |
Why?
|
Mice, Knockout | 1 | 2021 | 1918 | 0.040 |
Why?
|
Bronchoscopy | 1 | 2017 | 152 | 0.040 |
Why?
|
Patient Reported Outcome Measures | 1 | 2017 | 165 | 0.030 |
Why?
|
Decision Making | 1 | 2002 | 641 | 0.030 |
Why?
|
Cell Line | 2 | 2011 | 2466 | 0.030 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 411 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2015 | 67 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2005 | 2881 | 0.030 |
Why?
|
Receptors, IgG | 1 | 2015 | 52 | 0.030 |
Why?
|
Thalidomide | 1 | 2015 | 54 | 0.030 |
Why?
|
Safety | 2 | 2008 | 152 | 0.030 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2008 | 199 | 0.030 |
Why?
|
Human papillomavirus 18 | 1 | 2014 | 16 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2015 | 351 | 0.030 |
Why?
|
PAX8 Transcription Factor | 1 | 2014 | 23 | 0.030 |
Why?
|
Protein Interaction Maps | 1 | 2014 | 48 | 0.030 |
Why?
|
Erythrocyte Count | 1 | 2013 | 23 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2014 | 171 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2014 | 160 | 0.030 |
Why?
|
Autopsy | 1 | 2013 | 116 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2015 | 456 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 192 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 217 | 0.030 |
Why?
|
Gastrostomy | 1 | 2013 | 69 | 0.030 |
Why?
|
Drug Synergism | 1 | 2013 | 303 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 329 | 0.030 |
Why?
|
Ethers, Cyclic | 1 | 2012 | 7 | 0.030 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 2012 | 18 | 0.030 |
Why?
|
Alleles | 2 | 2006 | 1127 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2013 | 692 | 0.030 |
Why?
|
Bridged-Ring Compounds | 1 | 2012 | 13 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 3347 | 0.030 |
Why?
|
Thrombospondin 1 | 1 | 2011 | 21 | 0.030 |
Why?
|
GPI-Linked Proteins | 1 | 2011 | 50 | 0.030 |
Why?
|
Barrett Esophagus | 1 | 2012 | 93 | 0.030 |
Why?
|
Caenorhabditis elegans | 1 | 2014 | 222 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2012 | 303 | 0.030 |
Why?
|
Computational Biology | 1 | 2015 | 528 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2012 | 272 | 0.030 |
Why?
|
Drug Dosage Calculations | 1 | 2011 | 16 | 0.030 |
Why?
|
California | 1 | 2011 | 138 | 0.030 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2011 | 35 | 0.030 |
Why?
|
Lymphopenia | 1 | 2011 | 28 | 0.030 |
Why?
|
Organs at Risk | 1 | 2011 | 41 | 0.020 |
Why?
|
src-Family Kinases | 1 | 2011 | 74 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2013 | 291 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2013 | 615 | 0.020 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2011 | 63 | 0.020 |
Why?
|
Thorax | 1 | 2011 | 75 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2010 | 83 | 0.020 |
Why?
|
Endonucleases | 1 | 2010 | 21 | 0.020 |
Why?
|
Leucovorin | 1 | 2010 | 218 | 0.020 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2010 | 70 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2015 | 3029 | 0.020 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2010 | 35 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2010 | 63 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 115 | 0.020 |
Why?
|
Peptides | 1 | 2013 | 639 | 0.020 |
Why?
|
Hospitals, Veterans | 1 | 2009 | 17 | 0.020 |
Why?
|
Lymphoma, Follicular | 1 | 2010 | 70 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2010 | 78 | 0.020 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2010 | 106 | 0.020 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2009 | 6 | 0.020 |
Why?
|
Wound Healing | 1 | 2012 | 342 | 0.020 |
Why?
|
Semaphorins | 1 | 2009 | 17 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2009 | 49 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 153 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 136 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2010 | 279 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2010 | 363 | 0.020 |
Why?
|
Darbepoetin alfa | 1 | 2008 | 5 | 0.020 |
Why?
|
Phorbol Esters | 1 | 2008 | 22 | 0.020 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2009 | 28 | 0.020 |
Why?
|
Demography | 1 | 2009 | 177 | 0.020 |
Why?
|
Hematinics | 1 | 2008 | 11 | 0.020 |
Why?
|
Protein Kinase C beta | 1 | 2008 | 16 | 0.020 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 151 | 0.020 |
Why?
|
Pneumonia | 1 | 2010 | 178 | 0.020 |
Why?
|
Filgrastim | 1 | 2008 | 56 | 0.020 |
Why?
|
Bone Marrow | 1 | 2010 | 434 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2008 | 64 | 0.020 |
Why?
|
Community Health Services | 1 | 2009 | 80 | 0.020 |
Why?
|
Cell Cycle | 1 | 2010 | 502 | 0.020 |
Why?
|
Postoperative Care | 1 | 2009 | 220 | 0.020 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2008 | 43 | 0.020 |
Why?
|
Blotting, Western | 1 | 2010 | 781 | 0.020 |
Why?
|
Genes, erbB-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 178 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2010 | 679 | 0.020 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2008 | 79 | 0.020 |
Why?
|
Blood Pressure | 1 | 2013 | 1143 | 0.020 |
Why?
|
Exons | 1 | 2009 | 450 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2008 | 305 | 0.020 |
Why?
|
Topotecan | 1 | 2007 | 45 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2008 | 141 | 0.020 |
Why?
|
Health Transition | 1 | 2007 | 2 | 0.020 |
Why?
|
Fluoroscopy | 1 | 2007 | 119 | 0.020 |
Why?
|
Tamoxifen | 1 | 2008 | 167 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2009 | 377 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2008 | 1040 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2008 | 211 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2009 | 579 | 0.020 |
Why?
|
Aging | 1 | 2011 | 689 | 0.020 |
Why?
|
Video Recording | 1 | 2007 | 190 | 0.020 |
Why?
|
Stem Cells | 1 | 2008 | 350 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2008 | 363 | 0.020 |
Why?
|
Body Mass Index | 1 | 2009 | 770 | 0.020 |
Why?
|
Urogenital Neoplasms | 1 | 2005 | 22 | 0.020 |
Why?
|
Mandibular Diseases | 1 | 2005 | 16 | 0.020 |
Why?
|
Global Health | 1 | 2007 | 193 | 0.020 |
Why?
|
Up-Regulation | 1 | 2008 | 710 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2005 | 205 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 1 | 2005 | 81 | 0.020 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2005 | 106 | 0.020 |
Why?
|
Pleural Effusion | 1 | 2004 | 45 | 0.020 |
Why?
|
Imatinib Mesylate | 1 | 2005 | 126 | 0.020 |
Why?
|
Receptors, Endothelin | 1 | 2004 | 13 | 0.020 |
Why?
|
Antidiarrheals | 1 | 2004 | 14 | 0.020 |
Why?
|
Genital Neoplasms, Female | 1 | 2005 | 107 | 0.020 |
Why?
|
Research | 1 | 2005 | 253 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2008 | 532 | 0.020 |
Why?
|
Biomedical Research | 1 | 2008 | 375 | 0.020 |
Why?
|
Benzamides | 1 | 2005 | 226 | 0.020 |
Why?
|
Bilirubin | 1 | 2004 | 124 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2005 | 298 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 1611 | 0.010 |
Why?
|
Gadolinium DTPA | 1 | 2004 | 261 | 0.010 |
Why?
|
Risk | 1 | 2004 | 673 | 0.010 |
Why?
|
Biological Availability | 1 | 2002 | 92 | 0.010 |
Why?
|
Hematologic Neoplasms | 1 | 2005 | 329 | 0.010 |
Why?
|
Cytokines | 1 | 2006 | 775 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2007 | 1796 | 0.010 |
Why?
|
Child | 1 | 2012 | 6913 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2004 | 448 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2005 | 1562 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2004 | 554 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2004 | 739 | 0.010 |
Why?
|
Liver | 1 | 2004 | 1229 | 0.010 |
Why?
|
Phenotype | 1 | 2005 | 2375 | 0.010 |
Why?
|
Genetic Variation | 1 | 2004 | 1349 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2005 | 2267 | 0.010 |
Why?
|